March 02, 2015 12:31 AM ET

Biotechnology

Company Overview of Afferent Pharmaceuticals, Inc.

Company Overview

Afferent Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of small molecule compounds that target P2X3 receptors for the treatment of chronic pain, respiratory, and urological conditions. Its products include AF-219 that is used for patients with osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis/bladder pain syndrome; and AF-220, a second-generation P2X3 antagonist. The company was founded in 2009 and is based in San Mateo, California.

2755 Campus Drive

Suite 100

San Mateo, CA 94403

United States

Founded in 2009

Phone:

650-286-1276

Fax:

650-286-1833

Key Executives for Afferent Pharmaceuticals, Inc.

Chief Executive Officer and Director
Co-Founder and Chief Scientific Officer
Chief Medical Officer
Age: 64
Vice President of Clinical Operations
Compensation as of Fiscal Year 2014.

Afferent Pharmaceuticals, Inc. Key Developments

Afferent Pharmaceuticals Elects K. Peter Hirth as Board of Director

Afferent Pharmaceuticals announced the election of K. Peter Hirth, Ph.D., to Afferent's Board of Directors. Dr. Hirth has more than 30 years of drug discovery and development experience in the biotechnology and pharmaceutical industries, and has built several successful biotech companies. Dr. Hirth co-founded Plexxikon Inc., with operations starting in 2001 and serving as CEO until May 2013. During Dr. Hirth's tenure, Plexxikon discovered and advanced several NCEs to the clinic in a variety of indications, including a selective BRAF inhibitor approved by the FDA and sold under the brand name ZelborafTM along with a companion diagnostic. Plexxikon was acquired by Daiichi Sankyo in 2011. Prior to this, Dr. Hirth was president of SUGEN, Inc.

Afferent Pharmaceuticals, Inc. Announces Executive Changes

Afferent Pharmaceuticals, Inc. announced that Kathleen Sereda Glaub has been named as Chief Executive Officer. Ms. Glaub had been serving as an independent member of Afferent's Board since 2013, and she will continue to serve on the Board. She is replacing Bruce G. McCarthy, M.D., who served as the company's CEO since 2009. Prior to joining Afferent, Ms. Glaub most recently co-led Plexxikon Inc. as President.

Afferent Pharmaceuticals, Inc. Announces Management Appointments

Afferent Pharmaceuticals announced that Michael M. Kitt, M.D., has been named to the newly created position of Chief Medical Officer, effective immediately. In addition, Afferent announced the appointment of Kathleen Sereda Glaub to the Company's Board of Directors, expanding the number of Company directors to six. Dr. Kitt has over 30 years' experience in drug development with a proven record of success in running clinical trial programs and taking compounds through to NDA approval. He most recently served as Senior Vice President, Clinical Research and Regulatory Affairs and Chief Medical Officer at Portola Pharmaceuticals, Inc., where he led the planning and initiation of an international Phase 3 clinical program for the company's lead product candidate. Ms. Glaub has over 30 years of management and company-building experience for biopharma and innovation-based companies. Most recently, she co-led Plexxikon Inc. as President, a position she held for 12 years. During her tenure, Ms. Glaub was responsible for the business and financing strategy of the company leading its venture and partnership transactions, and ultimately leading the sale of the company to Daiichi Sankyo for nearly $1 billion in 2011. She also played a pivotal role in the company's product development programs, including the development of the company's melanoma drug Zelboraf and its companion diagnostic. She also put in place the commercial infrastructure and sales force to support the co-promotion of Zelboraf for the product launch in 2011.

Similar Private Companies By Industry

Company Name Region
SphynKx Therapeutics LLC United States
CDI Bioscience, Inc. United States
Berkeley Bioengineering Co. United States
DermTech, Inc. United States
Sirnaomics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Afferent Pharmaceuticals, Inc., please visit www.afferentpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.